Home   /  Find a Trial  /  See All Trials HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page  Print

see All Trials

Sort by zip code:  

 

Share

Facebook
Twitter

 
35 trials contain the search term(s): "PD-L1"

ABBV-181: An Immunotherapy Drug for Advanced Breast (and Other Solid) Tumors

A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-181, a Monoclonal Antibody , in Subjects With Advanced Solid Tumors (NCT03000257)

Summary

To take part in this study, you must have metastatic (stage IV) or locally advanced (some types of stage III) breast cancer that cannot be removed by surgery. This study is looking at whether a new type of immunotherapy drug is safe and effective in patients with metastatic or locally advanced breast cancer. The study will also determine the best dose of the drug to use. The drug is called ABBV-181. It is only available in clinical trials. This study is also enrolling patients with other types of advanced cancer. This study has two parts. If you are in the first part, called the dose escalation phase, you can take part if you have already been treated with PD-1/PD-L1 immunotherapy drugs. If you are in the second part, called the dose expansion phase, you cannot have had any PD-1/PD-L1 immunotherapy drugs.


This is a Phase I trial

MEDI4736 & Lynparza in Metastatic HER2- Breast Cancer in Women with a BRCA Mutation

A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Olaparib (PARP Inhibitor) in Patients With Advanced Solid Tumors (NCT02734004)

Summary

Olaparib (Lynparza) is a new type of targeted therapy called a PARP inhibitor. It works by blocking the PARP protein from repairing damaged DNA in cancer cells. Lynparza is approved for treating advanced ovarian cancer in women with a BRCA mutation. MEDI4736 is an immunotherapy that blocks PD-L1 (programmed cell death-ligand 1) protein. Blocking this protein stimulates the immune system to go after cancer cells. This study is investigating the safety and effectiveness of using Lynparaza and MEDI4736 together to treat women with HER2-negative metastatic breast cancer who have a BRCA1 or BRCA2 mutation.


This is a Phase I-II trial

Personalized Cancer Vaccine plus Atezolizumab for Advanced Breast (and Other) Tumors

A Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors (NCT03289962)

Summary

To take part in this study, you must have triple negative, locally advanced (some stage III) or metastatic (stage IV) breast cancer. This study is investigating the safety and effects (good or bad) of using a personalized cancer vaccine alone or with an immunotherapy to treat advanced breast cancer. The personalized cancer vaccine is called RO7198457. The immunotherapy being used in this study is the PD-L1 inhibitor atezolizumab (Tecentriq®). It works by blocking the PD-L1 (programmed cell death-ligand 1) protein and is approved to treat certain types of bladder and lung cancer. This study is also recruiting patients with other types of solid tumors.


This is a Phase I trial

Tecentriq and Paclitaxel for Triple Negative Advanced Breast Cancer

A Phase III, Multicenter, Randomised, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-Pd-L1 Antibody) in Combination With Paclitaxel Compared With Placebo With Paclitaxel for Patients With Previously Untreated Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer (NCT03125902)

Summary

To take part in this study, you must have recently been diagnosed with triple negative (ER-/PR-/HER2-) advanced (some stage III) or metastatic (stage IV) breast cancer and not yet started treatment. This study is investigating whether a chemotherapy drug works better when it is given along with an immunotherapy. The chemotherapy drug being used in this study is paclitaxel (Taxol®). It is used to treat breast cancer. The immunotherapy drug being used in this study is atezolizumab (Tecentriq®). It is a PD-L1 inhibitor that is currently approved to treat certain types of bladder and lung cancer.


This is a Phase III trial

Tecentriq & Cotellic or Idasanutlin for ER+, HER2- Advanced Breast Cancer

BRE 17107: A Phase Ib/II Trial of Atezolizumab (an Anti-PD-L1 Monoclonal Antibody) With Cobimetinib (a MEK1/2 Inhibitor) or Idasanutlin (an MDM2 Antagonist) in Metastatic ER+ Breast Cancer (NCT03566485)

Summary

To take part in this study, you must have ER positive advanced (some stage III) or metastatic (stage IV) breast cancer.

This study is investigating the safety and effects (good or bad) of giving an immunotherapy along with a targeted therapy. The immunotherapy used in this study is the PD-L1 inhibitor atezolizumab (Tecentriq®). It works by stimulating the body's immune system to go after cancer cells. It is approved to treat certain types of cancers but its use in breast cancer is considered experimental. The two targeted therapies being used in this study are cobimetinib (Cotellic®), an MEK-targeted therapy approved to treat melanoma, and idasanutlin, a targeted therapy being studied in clinical trials.


This is a Phase I-II trial

KY1044 and Atezolizumab Immunotherapy for Advanced Triple Negative Breast Cancer

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies (NCT03829501)

Summary

To take part in this study you must have advanced (some stage III) or metastatic (stage IV) triple negative (ER-/PR-/HER2-) breast cancer that has not responded to other treatment options.

This study is evaluating the safety and the effects (good or bad) of using KY1044 alone or with Tecentriq® (atezolizumab) to treat advanced breast cancer. KY1044 stimulates immune cells to go after and kill cancer cells. It also kills the T regulatory cells that keep immune cells from killing the cancer cells. Tecentriq® (atezolizumab) is a type of immunotherapy called a PD-L1 (programmed cell death-ligand 1) inhibitor. It is approved to treat advanced triple negative breast cancer, as well as certain types of bladder and lung cancer.


This is a Phase I-II trial

MEDI4736 with Lynparza or Cediranib for Advanced Breast (and Other Solid) Tumors

Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancer (NCT02484404)

Summary

MEDI4736 (durvalumab) is an immunotherapy drug that works by blocking a protein called PD-L1 (programmed cell death ligand-1). Blocking this protein allows the body's immune system to go after cancer cells. Olaparib (Lynparza®) is a type of cancer drug called a PARP inhibitor. PARP inhibitors interfere with the cancer cells' DNA, making them more sensitive to chemotherapy. Lynparza is used to treat advanced ovarian cancer in women who have an inherited BRCA1/2 mutation. In phase 1 of this study, researchers studied the safety and effectiveness of using MEDI4736, Lynparza or cediranib to treat advanced breast (and other solid) tumors. Phase 1 is now completed. Phase 2 of this study is open to triple-negative breast cancer patients combining MEDI4736 and olaparib. To be eligible, patients must not have previously been treated with PARP inhibitors, PD-1 or PD-L1 inhibitor or an anti-CTLA4 therapy and not have had more than 3 lines of previous treatments for metastatic disease.


This is a Phase I-II trial

Chemotherapy plus Atezolizumab Before Surgery for Newly Diagnosed Stage II-III TNBC

Randomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, With or Without Atezolizumab in Triple Negative Breast Cancer (TNBC) (NCT02883062)

Summary

To take part in this study, you must have recently been diagnosed with triple negative (ER-/PR-/HER2-) stage II-III breast cancer and not yet started treatment. You must also be able to have chemotherapy before surgery (mastectomy or lumpectomy). This study is comparing the the safety and effect (good or bad) of giving chemotherapy and immunotherapy before surgery to giving chemotherapy alone before surgery to treat early stage triple negative breast cancer. Atezolizumab (Tecentriq®) is the immunotherapy used in this study. It is a PD-L1 inhibitor approved to treat certain types of bladder and lung cancer. It works by blocking the PD-L1 (programmed cell death-ligand 1) protein. The chemotherapy drugs used in this study are carboplatin (Paraplatin®) and paclitaxel (Taxol®). They are both used to treat breast cancer.


This is a Phase II trial

Paclitaxel, Trastuzumab, Pertuzumab With or Without Atezolizumab For HER2+ Metastatic Breast Cancer

A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer (NCT03199885)

Summary

To take part in this study you must be starting treatment for metastatic (stage IV) breast cancer or have had your breast cancer recur after 6 months of neoadjuvant or adjuvant HER2-targeted therapy.

This study is comparing the safety and effects of the combination of pembrolizumab, trastuzumab, paclitaxel, and atezolizumab with the combination of pembrolizumab, trastuzumab, paclitaxel, and a placebo. Pembrolizumab (Keytruda®) is a type of immunotherapy called a PD-L1 inhibitor. It is approved to treat certain types of cancer. Its use in breast cancer is considered experimental. Trastuzumab (Herceptin®) is a HER2-targeted therapy used to treat HER2-positive breast cancer. Paclitaxel (Taxol®) is a chemotherapy drug routinely used to treat breast cancer. Atezolizumab (Tecentriq®) is a type of immunotherapy called a PD-L1 inhibitor.


This is a Phase III trial

Tecentriq with Chemotherapy After Surgery for Stage II-III Triple-Negative Breast Cancer

A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti PD-L1 Antibody) in Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone in Patients With Operable Triple Negative Breast Cancer (NCT03498716)

Summary

To take part in this study, you must have stage II-III triple negative (ER-/PR-/HER2-) breast cancer. This study is comparing the safety and effectiveness of using an immunotherapy drug along with chemotherapy to chemotherapy alone to treat stage II-III triple negative breast cancer. Atezolizumab (Tecentriq®) is the immunotherapy drug used in this study. It gets the immune system to attack cancer cells by blocking a protein called PD-L1 (programmed cell death-ligand 1). It is used to treat some lung and bladder cancers. Your first chemotherapy drug will be paclitaxel (Taxol®). It will be followed by dose-dense chemotherapy. Your doctor will decide if you receive doxorubicin (Adriamycin®) or epirubicin (Ellence®) and cyclophosphamide (Cytoxan®). You will also receive GM-CSF (sargramostim) or G-CSF (filgrastim) to prevent neutropenia--a low white blood cell count that increases your risk for infection.


This is a Phase III trial

Chemotherapy before Surgery with Atezolizumab for Triple Negative Breast Cancer

A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo (NCT03281954)

Summary

To take part in this study, you must have triple negative (ER-/PR-/HER2-), early stage (stage I-III) breast cancer. This study is comparing the safety and effects (good or bad) of using an immunotherapy and the standard of care chemotherapy with using a placebo and the standard of care chemotherapy before and after surgery to treat early-stage triple negative breast cancer. The immunotherapy used in this study is atezolizumab (Tecentriq®). It is a PD-L1 inhibitor approved to treat certain types of bladder and lung cancer. It works by blocking the PD-L1 (programmed cell death-ligand 1) protein.The standard of care chemotherapy drugs used in this study are paclitaxel (Taxol®) and carboplatin (Paraplatin®) followed by doxorubicin (Adriamycin®) and cyclophosphamide (Cytoxan®) or epirubicin (Ellence®) and cyclophosphamide.


This is a Phase III trial

Olaparib and Durvalumab for Metastatic Triple Negative Breast Cancer

A Pilot Study of Olaparib and Durvalumab in Patients With Metastatic Triple Negative Breast Cancer (NCT03544125)

Summary

To take part in this study, you must have metastatic (stage IV) triple negative (ER-/PR-/HER2-) breast cancer. You must not have had prior treatment with anti-PD-L1, anti-PD-1, anti-CTLA4 therapies or PARP inhibitors. This study is investigating the effects of using a targeted therapy followed by an immunotherapy to treat metastatic triple negative breast cancer. The targeted therapy being used is the PARP inhibitor olaparib (Lynparza®). It is approved to treat BRCA+, HER2- breast cancer. The immunotherapy being used in this study is durvalumab (Imfinzi®). It works by stimulating the body's immune system to go after cancer cells. It is approved to treat certain types of lung cancer.
This is a Phase I trial

Immunotherapy LY3300054 Alone and in Combination in Advanced Breast Cancer

A Phase 1a/1b Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination With Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT) (NCT02791334)

Summary

To take part in this study you must have locally advanced (stage III) or metastatic (stage IV) breast cancer that is hormone receptor positive and HER2-negative or tests positive for high microsatellite instability (MSI-H). You must also have had at least 1 but no more than 3 chemotherapy regimens in the metastatic setting.

This study is testing the safety and effects (good or bad) of LY3300054 when it is used alone or in combination with a targeted therapy or an immunotherapy. LY3300054 is a type of immunotherapy called a checkpoint inhibitor. There are three other drugs being used in this study. LY3321367 is also an investigational checkpoint inhibitor. Ramucirumab (Cyramza) is a targeted therapy that blocks VEGFR-2, which keeps tumors from forming new blood vessels. It is approved to treat certain types of solid tumors, but not breast cancer. Abemaciclib (Verzenio) is a CDK 4/6 inhibitor approved to treat HR positive and HER2-negative metastatic breast cancer.


This is a Phase I trial

MEDI4736 and Chemotherapy Before Surgery for Stage I-III Triple Negative Breast Cancer

Single Arm Neoadjuvant Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) Concomitant With Weekly Nab-paclitaxel and Dose-dense Doxorubicin/Cyclophosphamide (ddAC) Chemotherapy for Clinical Stage I-III Triple Negative Breast Cancer (NCT02489448)

Summary

MEDI4736 is a new immunotherapy drug. By blocking a protein called PD-1 (programmed cell death 1), it allows the immune system to go after cancer cells. Doxorubicin (Adriamycin®) and cyclophosphamide (Cytoxan®)--known as AC chemotherapy--and nab-paclitaxel (Abraxane®) are routinely used to treat breast cancer. Giving MEDI4736 with this chemotherapy regimen before surgery (called neoadjuvant therapy) may make the chemotherapy more effective. This study will investigate the best dose and effectiveness of MEDI4736 for use with this chemotherapy regimen when it is given before surgery to individuals with stage I-III triple negative breast cancer.


This is a Phase I-II trial

M7824 and Halaven for Metastatic Triple Negative Breast Cancer

A Phase Ib Trial of M7824 and Eribulin in Patients With Metastatic Triple Negative Breast Cancer (TNBC) (NCT03579472)

Summary

To take part in this study you must be a woman or man with triple negative (ER- PR- HER2-) metastatic (stage IV) breast cancer

This study is designed to find the best dose of M7824 to use with eribulin (Halaven). M7824 is an investigational immunotherapy drug. It gets immune cells to see cancer cells by blocking PD-L1 and TGF-beta. Halaven is used to treat patients who have already had at least two other anticancer medicines for their metastatic breast cancer and who have already been treated with an anthracycline and a taxane for either early or advanced breast cancer


This is a Phase I trial

Tecentriq and Stereotactic Radiosurgery for Triple Negative Breast Cancer Brain Mets

A Phase II Study of Atezolizumab in Combination With Stereotactic Radiosurgery for Patients With Triple-negative Breast Cancer and Brain Metastasis (NCT03483012)

Summary

To take part in this study, you must have metastatic (stage IV), triple negative (ER-/PR-/HER2-) breast cancer that has spread to the brain. This study is investigating the effectiveness of treating breast cancer brain metastases with stereotactic radiosurgery and an immunotherapy drug. Stereotactic radiosurgery delivers focused radiation to each individual brain metastasis. It is routinely used to treat brain metastases. The immunotherapy drug being used in this study is atezolizumab (Tecentriq®) It gets the immune system to go after cancer cells by blocking a protein called PD-L1 (programmed cell death-ligand 1). It is approved to treat certain types of bladder cancer and lung cancer.


This is a Phase II trial

Avelumab Plus Talazoparib to Treat Advanced Breast Cancer

A Phase 1b/2 Study To Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors (NCT03330405)

Summary

To take part in this study, you must have triple negative (ER-/PR-/HER2-) or HR+, locally advanced (some stage III) or metastatic (stage IV) breast cancer. This study is investigating the safety and effects (good or bad) of using an immunotherapy along with a targeted therapy to treat advanced breast cancer. The immunotherapy being used in this study is abelumab (Bavencio®). It works by blocking a protein called PD-L1 (programmed cell death-ligand 1). Talazoparib (BMN-637) is a type of targeted therapy called a PARP inhibitor. It prevents the PARP protein from repairing damaged DNA in tumor cells. This study is also enrolling patients with other types of solid tumors.
This is a Phase II trial

NIS793 with Spartalizumab (PDR001) in Patients With Advanced Triple Negative Breast Cancer

A Phase I/Ib, Open-label, Multi-center Dose Escalation Study of NIS793 in Combination With PDR001 in Adult Patients With Advanced Malignancies (NCT02947165)

Summary

To take part in this study you must have locally advanced (stage III) or metastatic (stage IV) triple negative breast cancer (ER-, PR- and HER2-) and have no other standard treatment options available.

This study is investigating the safety, effects (good or bad) and best dose of NIS793 when it is used alone or with an immunotherapy. NIS793 is a targeted therapy that binds to the transforming growth factor-beta receptor. Spartalizumab is the investigational immunotherapy being used in this study. It is a type of immunotherapy called a PD-L1 checkpoint inhibitor. This study is also enrolling patients with other types of solid tumors.


This is a Phase I trial

Keytruda plus Abraxane Before Surgery for ER+ or PR+ Stage II or III Breast Cancer

A Pilot Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer (NCT02999477)

Summary

To take part in this study, you must have HR-positive (ER+ and/or PR+), HER2-negative stage II or III breast cancer that can be removed by surgery. This study is investigating the safety and effect of different combinations of Keytruda® and Abraxane® when they are given before surgery to patients with stage II or III breast cancer. Pembrolizumab (Keytruda®) is an immunotherapy drug. It gets the body's immune system to go after cancer cells by blocking a protein called programmed cell death (PD-1). It is currently approved to treat certain types of melanoma, head and neck cancer, lung cancer and Hodgkin lymphoma. Nab-paclitaxel (Abraxane®) is a chemotherapy drug approved to treat metastatic breast cancer in patents who have already tried other cancer treatments.
This is a Phase I trial

Olaparib and Durvalumab in Metastatic Triple Negative Breast Cancer

A Phase II, Open Label, Study of Olaparib and Durvalumab (MEDI4736) in Patients With Metastatic Triple Negative Breast Cancer (NCT03801369)

Summary

To take part in this study you must have metastatic (stage IV) triple negative (ER-/PR-/HER2-) breast cancer.

This study is evaluating the safety and effects (good or bad) of using the combination of olaparib (Lynparza®) and durvalumab (Imfinzi®). Lynparza is a PARP inhibitor. It stops the growth of cancer cells by blocking enzymes called poly ADP ribose polymerase (PARP). It is approved to treat certain types of ovarian cancer. Imfinzi is a type of immunotherapy drug called a PD-L1 inhibitor. It gets the body's immune system to go after cancer cells. It is approved to treat certain types of lung cancer. Preclinical studies suggest this drug combination may be effective in patients with metastatic triple negative breast cancer.


This is a Phase II trial

Tecentriq, Perjeta and Hercptin for HER2+ Breast Cancer That Has Spread to the Brain

A Phase II Study of Atezolizumab in Combination With Pertuzumab Plus High-dose Trastuzumab for the Treatment of Central Nervous System Metastases in Patients With Her2-positive Breast Cancer(NCT03417544)

Summary

To take part in this study, you must have HER2-positive, metastatic (stage IV) breast cancer that has spread to the brain. This study is evaluating the safety and effects (good or bad) of using an immunotherapy drug along with a HER2 targeted drug to treat HER2+ metastatic breast cancer. The immunotherapy drug is atezolizumab (Tecentriq®). It is approved to treat certain types of lung and bladder cancers. It gets the immune system to go after cancer cells by blocking a protein called PD-L1 (programmed cell death-ligand 1). The two HER2-targeted drugs used in this study are pertuzumab (Perjeta®) and trastuzumab (Herceptin®).
This is a Phase II trial

Using Two Immunotherapy Drugs to Treat Metastatic Triple Negative Breast Cancer

A Phase 1b/2 Open-Label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies (NCT02554812)

Summary

Using two immunotherapy drugs together may kill more cancer cells than using one alone. Avelumab and PF-05082566 are two new immunotherapy drugs now in clinical trials. Both work by blocking a protein called PD-L1. Blocking this protein allows the immune system to find and kill cancer cells. This study is investigating the safety of avelumab and the best dose of it to use along with PF-05082566. To take part in this study, you must have metastatic triple negative (ER-negative, PR-negative, HER2-negative) breast cancer. This study also is enrolling patients with other types of solid tumors. Some of these patients will receive the immunotherapy drug PF-04518600 along with avelumab.


This is a Phase II trial

A Vaccine and Durvalumab After Surgery for Stage II or III Triple Negative Breast Cancer

A Phase 1b Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination With Durvalumab in Human Leukocyte Antigen (HLA)-A2+ Subjects Following Standard Treatment of Stage II or III Triple Negative Breast Cancer (NCT02826434)

Summary

To take part in this study, you must have been diagnosed with stage II or III triple negative (ER-/PR-/HER2-) breast cancer and have already received the standard treatment for your tumor's stage. This study is looking at whether it is safe and effective to combine two different types of immunotherapy--a vaccine and a targeted drug. The vaccine being studied is called PVX-410. It is only available in clinical trials. The targeted drug is durvalumab. It is being studied in clinical trials for breast and other types of cancer. It blocks a protein called PD-L1 (programmed cell death ligand-1).


This is a Phase I trial

Atezolizumab & Abraxane for Triple Negative Stage I-III Breast Tumors

Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A, a Pdl-1 Inhibitor in Patients With Triple Negative Breast Cancer (NCT02530489)

Summary

MPDL3280A (atezolizumab) is an new immunotherapy drug that stimulates the body's immune system to go after cancer cells. It works by blocking a protein called programmed cell death ligand-1 (PD-L1) that normally keeps the body's immune system from attacking and destroying tumor cells. Nab-paclitaxel (Abraxane®) is a chemotherapy drug routinely used to treat advanced breast cancer. This study is looking at the safety and effectiveness of using atezolizumab and Abraxane before surgery and then using atezolizumab after surgery to treat stage I-III triple-negative breast cancer. Participants must have not had significant tumor shrinkage from enrollment in another study at M.D. Anderson (NCT02276443) to be eligible for this study.


This is a Phase II trial

Tecentriq, Cotellic & Halaven for Metastatic Inflammatory Breast Cancer

A Phase II Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) in Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer (NCT03202316)

Summary

To take part in this study, you must have inflammatory advanced (some stage III) or metastatic (stage IV) breast cancer. You must also have already been treated with a chemotherapy that your cancer progressed on or did not respond to. In this study, researchers will determine the safety and effect (good or bad) of using a combination of immunotherapy, targeted therapy and chemotherapy to control metastatic inflammatory breast cancer. Atezolizumab (Tecentriq®) is a type of immunotherapy called a PD-L1 inhibitor. It is FDA approved to treat certain types of bladder and lung cancer. Cobimetinib (Cotellic®) is a new targeted therapy called an MEK inhibitor. It is approved to treat certain types of melanoma. Eribulin (Halaven®) is a chemotherapy drug approved for treating metastatic breast cancer.


This is a Phase II trial

Durvalumab & Olaparib in Advanced Triple Negative Breast Cancer Treated with Chemotherapy

Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) (NCT03167619)

Summary

To take part in this study, you must have advanced (some stage III that is inoperable) or metastatic (stage IV) triple negative breast cancer (ER-, PR- and HER2-), have already been treated with at least three cycles of a platinum-based chemotherapy and shown response, and have had no more than two prior chemotherapy regimens for metastatic breast cancer.

This study will compare the effects (good or bad) of using the targeted therapy olaparib (Lynparza®) alone or with an immunotherapy drug. Lynparza is approved to treat HER2-negative metastatic breast cancer in patients who test positive for an inherited BRCA mutation. It is a PARP inhibitor, a drug that blocks the action of poly (ADP-ribose) polymerase, an enzyme that helps repair DNA. Durvalumab (Imfinzi®) is a type of immunotherapy called a PD-L1 (programmed cell death ligand-1) inhibitor. It has been approved to treat certain other types of cancers, and its use in breast cancer is considered experimental.


This is a Phase II trial

Ibrance, Bavencio and Faslodex for Previously Treated ER+, HER2- Advanced Breast Cancer

Palbociclib After CDK and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer (NCT03147287)

Summary

To take part in this study, you must have HR+, HER2-negative locally recurrent (some stage III) or metastatic (stage IV) breast cancer. You must have already been treated with a CDK4/6 inhibitor in combination with an anti-estrogen therapy. This study is investigating the safety and effects (good and bad) of using fulvestrant (Faslodex®) alone, in combination with Ibrance®, and in combination with Ibrance and Bavencio®. Faslodex is the anti-estrogen drug used in this study. Palbociclib (Ibrance®) is approved to treat HR+, HER2-negative breast cancer in combination with an anti-estrogen therapy. Avelumab (Bavencio®) is a type of immunotherapy called a PD-L1 inhibitor. It is approved to treat a type of blood cancer.
This is a Phase II trial

Veliparib and/or Tecentriq for BRCA+, Stage III-IV Triple Negative Breast Cancer

A Phase II Multiple-Arm, Open-Label, Randomized Study of PARP Inhibition (Veliparib; ABT-888) and Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) Either Alone or in Combination in Homologous DNA Repair (HDR) Deficient Triple Negative Breast Cancer (TNBC) (NCT02849496)

Summary

To take part in this study, you must have stage III or IV triple negative (ER-/PR-/HER2-) breast cancer. You must also test positive for the inherited BRCA1/2 mutation. This study is investigating how well two different types of cancer drugs work when they are used alone or together to treat stage III or IV triple negative breast cancer. The two drugs being used in this study are Veliparib (ABT-888) and atezolizumab (Tecentriq). Veliparib (ABT-888) is a new type of targeted drug called a PARP inhibitor. It is available only in clinical trials. Tecentriq is a new immunotherapy drug. It is approved to treat bladder cancer and a type of lung cancer.


This is a Phase II trial

Immunotherapy for Metastatic Triple Negative Breast (and Other) Cancers

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers (NCT02655822)

Summary

Many tumors produce a lot of adenosine, a molecule that interacts with the immune system and keeps immune cells from going after cancer cells. CPI-444 is a new type of immunotherapy drug. It keeps adenosine from being able to tell the immune cells not to go after cancer cells. Atezolizumab (MPDL3280A) is another new immunotherapy drug. It blocks a protein called programmed cell death ligand-1 (PD-L1). Blocking this protein allows the body's immune system to go after cancer cells. This study is looking at the safety and effect of different scheduling cycles for CPI-444 as well as the safety and effect of giving CPI-444 along with MPDL3280A.


This is a Phase I trial

Tamoxifen, Palbociclib, Avelumab Before Surgery in ER Positive Breast Cancer

A Pilot Study of IMMUNe mOdulation in Early Stage Estrogen Receptor Positive Breast Cancer Treated With neoADjuvant Avelumab, Palbociclib, and Tamoxifen: The ImmunoADAPT Study (NCT03573648)

Summary

To take part in this study you must have stage II or stage III ER-positive breast cancer that will be treated with surgery.

This study is investigating whether giving tamoxifen and avelumab before surgery shrinks tumors more than the combination of tamoxifen, avelumab and palbociclib. Tamoxifen (Nolvadex®) is a hormonal therapy used to treat ER-positive breast cancer. Avelumab (Bavencio®) is a type of immunotherapy drug called a PD-L1 inhibitor. It is approved to treat non-small-cell lung cancer. Its use in breast cancer is considered experimental. Palbociclib (Ibrance®) is a CDK inhibitor. It is approved to treat ER-positive, HER2-negative metastatic breast cancer. Giving therapies before surgery, called neoadjuvant treatment, allows researchers to measure how tumors respond to different therapies.


This is a Phase II trial

Herceptin and Navelbine With Immunotherapy for Advanced HER2+ Breast Cancer

A Randomized, Phase II Study Comparing Trastuzumab and Vinorelbine in Combination With Avelumab or Avelumab and Utomilumab (41BB/CD137 Agonist), in Patients With HER2-positive Metastatic Breast Cancer Who Have Progressed on Prior Trastuzumab and Pertuzumab (NCT03414658)

Summary

To take part in this study, you must have HER2 positive advanced (stage III) or metastatic (stage IV) breast cancer. This study is investigating the safety and effects (good or bad) of three different drug combinations in advanced HER2 positive breast cancer. The drugs being used in this study are: trastuzumab (Herceptin®), vinorelbine (Navelbine®) avelumab (Bevancio®) and utomilumab (PF-05082566). Herceptin is a targeted therapy routinely used to treat HER2-positive breast cancer. Navelbine®) is a chemotherapy drug used to treat HER2-positive breast cancer. Avelumab (Bevancio®) and utomilumab (PF-05082566) are immunotherapies that work by stimulating the body's immune system to go after cancer cells. Both work by blocking a protein called PD-L1. Bevancio is approved to treat metastatic Merkel cell carcinoma and urothelial (bladder) cancers. It's use is considered experimental in breast cancer. Utomilumab is an experimental treatment.


This is a Phase II trial

Atezolizumab & Chemotherapy Before Surgery for Stage II-III Triple Negative Breast Cancer

A Phase III Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Neoadjuvant Anthracycline/Nab-Paclitaxel-Based Chemotherapy Compared With Placebo and Chemotherapy in Patients With Primary Invasive Triple-Negative Breast Cancer (NCT03197935)

Summary

To take part in this study, you must have been diagnosed with triple negative (ER-/PR-/HER2-) early stage (stage I-III) breast cancer and not yet started treatment. This study is comparing the safety and effects (good and bad) of using immunotherapy and chemotherapy to chemotherapy alone in triple negative breast cancer. The immunotherapy being used in this study is atezolizumab (Tecentriq®). It stimulates the body's immune system to go after cancer cells. The chemotherapy drugs being used in this study are nab-paclitaxel (Abraxane®) and AC chemotherapy (doxorubicin/Adriamycin® and cyclophosphamide/Cytoxan®). All three drugs are commonly used to treat breast cancer. Patients enrolled in this study will also receive filgrastim or pegfilgrastim to prevent neutropenia--a very low white blood cell count--from developing.


This is a Phase III trial

Atezolizumab Before & After Surgery for Stage II or III HER2 Positive Breast Cancer

A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer (IMpassion050) (NCT03726879)

Summary

To take part in this study you must have stage II or III HER2 positive breast cancer.

This study (known as IMpassion050) is comparing the safety, side effects, and effectiveness of using an immunotherapy drug or a placebo along with chemotherapy and HER2-targeted therapies. Atezolizumab (Tecentriq®) is the immunotherapy drug being used in this study. It is a PD-L1 (protein programmed cell death-ligand 1) inhibitor that has been approved to treat certain other types of cancers. The other therapies being used in this study are the chemotherapy drugs paclitaxel (Taxol®), doxorubicin (Doxil®), and cyclophosphamide (Cytoxan®), and the HER2-targeted therapies trastuzumab (Herceptin®) and pertuzumab (Perjeta®).


This is a Phase III trial

  • Participation TimeVisits every 2 or 3 weeks for 5 months before surgery, followed by visits every 3 weeks for 1 year
  • Participating research sites
    Research sites: 7 sites total

Combination of Immunotherapy and Targeted Therapies for HR+ and HER2- Breast Cancer

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Hormone Receptor-Positive HER2-Negative Breast Cancer (MORPHEUS-HR+ Breast Cancer) (NCT03280563)

Summary

To take part in this study, you must have HR-positive, HER2-negative advanced (some stage III) or metastatic (stage IV) breast cancer. You must also have already been treated with a cyclin-dependent kinase (CDK) 4/6 inhibitor such as palbociclib/Ibrance®, ribociclib/LEE011, or abemaciclib/LY2835219, that your cancer progressed on or did not respond to. This trial is studying 5 different treatment options. Women will receive one, two, or three of the following drugs: the immunotherapy atezolizumab (Tecentriq®), a PD-L1 (programmed cell death-ligand 1) inhibitor approved to treat certain types of bladder and lung cancer; the targeted therapy cobimetinib (Cotellic), which blocks the MEK protein and is approved to treat certain types of melanoma; fulvestrant (Faslodex®), a standard chemotherapy used to treat breast cancer; ipatasertib (GDC-0068), a new type of cancer drug that works by blocking the Akt protein; bevacizumab (Avastin), a monoclonal antibody that keeps tumors from growing the blood vessels they need to survive and is used to treat HER2-negative metastatic breast cancer.


This is a Phase I-II trial

Tecentriq & Targeted Therapy or Chemotherapy for Metastatic Triple Negative Breast Cancer

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Triple-Negative Breast Cancer (Morpheus-TNBC) (NCT03424005)

Summary

To take part in this study, you must have triple negative (ER-/PR-/HER2-) advanced (some stage III) or metastatic (stage IV) breast cancer that progressed during or following first-line metastatic treatment with chemotherapy. This study is investigating the safety and effectiveness of 7 different immunotherapy-based treatment combinations in women and men with triple negative (ER-/PR-/HER2-) breast cancer. The immunotherapy being used in this study is atezolizumab (Tecentriq®). It is a PD-L1 inhibitor that works by stimulating the body's immune system to go after cancer cells. It is approved to treat certain types of urinary, bladder and lung cancer. The targeted therapies being used in the study are Ipatasertib (GDC-0068), SGN-LIV1A, bevacizumab (Avastin®) and cobimetinib (Cotellic®). The chemotherapies being used in this study are capecitabine (Xeloda®), gemcitabine (Gemzar®), carboplatin (Paraplatin®) and eribulin (Halaven®).


This is a Phase I-II trial